Pharmaceutical Chemistry Journal

, Volume 52, Issue 3, pp 271–277 | Cite as

Stability-Indicating UV-Spectrophotometric Assay of Diethylcarbamazine Citrate in Pharmaceuticals

  • K. Basavaiah
  • N. Swamy

Diethylcarbamazine citrate (DEC) is a piperazine anthelmintic agent indicated for the treatment of individual patients with lymphatic filariasis. Two simple and sensitive UV-spectrophotometric techniques have been developed and validated for the determination of this drug in bulk parent substance and tablets, based on the measurement of the absorbance of DEC solution either in 0.1M HCl at 210 nm (method A) or in 0.1M H2SO4 at 209 nm (method B). Beer’s law was obeyed over the concentration ranges of 1.25 – 25.0 and 2.5 – 30.0 μg · mL-1, for method Aand method B, respectively, and the corresponding molar absorptivity values were 2.02 × 104 and 1.21 × 104 L mol-1 · cm-1. The limits of detection (LOD) and quantification (LOQ) were, respectively, 0.26 and 0.78 μg · mL-1 (method A), and 0.16 and 0.49 μg · mL-1 (method B). These methods were assessed for intra-day and inter-day accuracy and precision, as well as robustness and ruggedness. Both methods were applied to one brand of tablets with percentage label claim of 101.7 and 100.8 for method A and method B, respectively, and the standard deviation was below 2%. In order to establish the stability-indicating ability of these methods, the drug was analyzed after subjecting it to acid and base hydrolysis, oxidation, heat and light stress conditions and the results indicated that the drug degraded extensively under both base- and oxidative-stress conditions, and remained intact under other stress conditions.


diethylcarbamazine citrate assay UV spectrophotometry stability-indicating method 



The authors are grateful to the quality control manager, Inga Laboratories Pvt. Ltd., Mumbai, India, for gift sample of pure diethylcarbamazine citrate and the authorities of the University of Mysore, Mysuru, for permission and facilities. Prof. K. Basavaiah thanks the University Grants Commission, New Delhi, India, for the award UGC-BSR Faculty Fellowship.From data in Figs. 48, it can be seen that the drug degraded extensively under base-hydrolysis and oxidative stress conditions, but remained stable under other stress conditions. These results are summarized in Table 6.


  1. 1.
    World Health Organization (WHO), Lymphatic filariasis: The Disease and Its Control, Technical Reports Series, No. 821, WHO, Geneva (1992).Google Scholar
  2. 2.
    E. A. Ottenson, The filariases and tropical eosinophilia, in K. S. Warren and A. D. F. Mahmoud (Eds.), Tropical and Geographical Medicine, 2 nd Edn., McGraw-Hill, New York (1990).Google Scholar
  3. 3.
    The British Pharmacopoeia, Her Majesty’s Stationery Office, London, England (1988), p. 190.Google Scholar
  4. 4.
    United States Pharmacopoeia, Monograph USP30-NF25 (p. 1929), Pharmacopoeial Forum, 28, 1098.Google Scholar
  5. 5.
    L. Bhanumathi, S. G. Wadodkar, and A. V. Kasture, Indian Drugs, 18(6), 204 – 206 (1981).Google Scholar
  6. 6.
    A. M. Wahbi, H. A. El-Obeid and E. A. Gad-Kariem, Farmaco Prat., 41(6), 210 – 214 (1986).PubMedGoogle Scholar
  7. 7.
    M. Rizk, M. I. Walash, and F. Ibrahim, Spectr. Lett., 17(8), 423 – 440 (1984).CrossRefGoogle Scholar
  8. 8.
    U. A. Michael, C. O. Kenneth, and A. A. Anthony, Chem. Pharm. Bull., 47(4), 463 – 466 (1999).CrossRefGoogle Scholar
  9. 9.
    M. Ramachandran, Curr. Sci., 41(24), 890 – 891 (1972).Google Scholar
  10. 10.
    I. H. Refaat, M. E. El-Kommos, H. H. Farag, and N. A. El-Rabat, Bull. Pharm. Sci., Assiut Univ., 10(2), 85 – 102 (1987).Google Scholar
  11. 11.
    M. V. Bulbule, A. V. Kasture, and S. G. Wadodkar, Indian Drugs, 19(1), 27 – 28 (1981).Google Scholar
  12. 12.
    G. S. Bhuee, S. N. Rastogi, U. K. Jetley, and J. Singh, East. Pharm., 24(277), 197 – 198 (1981).Google Scholar
  13. 13.
    K. Basu and B. N. Dutta, Indian J. Pharm., 23, 326 – 329, (1961).Google Scholar
  14. 14.
    C. S. P. Sastry, M. Aruna, M. N. Reddy, and D. G. Sankar, Indian J. Pharm. Sci., 50(2), 140 – 142 (1988).Google Scholar
  15. 15.
    D. J. Vadodaria, M. N. Vora, and S. P. Mukherji, Indian J. Pharm., 30(2), 41 – 43 (1968)Google Scholar
  16. 16.
    K. N. Rao and D. Subrahmanyam, Indian J. Med. Res., 58(6), 746 – 752 (1970).PubMedGoogle Scholar
  17. 17.
    N. Swamy, K. N. Prashanth, and K. Basavaiah, Inventi Impact: Pharm. Anal. Quality Assur., 2(2), 103 – 112 (2014).Google Scholar
  18. 18.
    W. Jezzy, D. B. Jaroszewski, A. Frank, et al., J. Pharm. Biomed. Anal., 14(5), 543 – 549 (1996).CrossRefGoogle Scholar
  19. 19.
    H. A. El-Obeid, Spectr. Lett., 17(6 – 7), 361 – 367 (1984).CrossRefGoogle Scholar
  20. 20.
    M. I. Walash, M. S. Rizk, and F. A. Ibrahim, J. Assoc. Off. Anal. Chem., 68(3), 532 – 534 (1985).PubMedGoogle Scholar
  21. 21.
    G. R. Rao, S. Raghuveer, and P. Khadgapathi, Indian Drugs, 24(1), 37 – 41 (1986).Google Scholar
  22. 22.
    N. Mathew and M. Kalyanasundaram, Acta Trop., 80(2), 97 – 102 (2001).CrossRefPubMedGoogle Scholar
  23. 23.
    D. Boopathy, D. Magham, B. Kumar, et al., Asian J. Res. Chem., 4(7), 1064 – 1066 (2011).Google Scholar
  24. 24.
    J. Mahesh Reddy, M. R. Jeyaprakash, K. Madhuri, et al., Indian J. Pharm. Sci., 73(3), 320–323 (2011).PubMedPubMedCentralGoogle Scholar
  25. 25.
    M. B. Krishna Vamsi, R. Jayalakshmi, A. Vijay, and C. Sandeep, IJPSR, 3(9), 3347 – 3353 (2012).Google Scholar
  26. 26.
    B. Daravath, G. S. Reddy and S. K. Kamarapu, Asian J. Pharm. Clin. Res., 7(3), 98 – 102 (2014).Google Scholar
  27. 27.
    G. S. Reddy, B. Daravath, and S. K. Kamarapu, Int. J. Pharm. Bio. Sci., 3(4), 216 – 223 (2013).Google Scholar
  28. 28.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R 1), Complementary Guideline on Methodology, dated 06 November 1996, incorporated in November 2005, London.Google Scholar
  29. 29.
    International Conference on Harmonization. Stability testing of new drug substances and products. International Conference on Harmonization, IFPMA, Geneva, Switzerland, 2003.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of ChemistryUniversity of Mysore, ManasagangothriMysuruIndia

Personalised recommendations